These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 22999414)

  • 21. Edoxaban: a focused review of its clinical pharmacology.
    Lip GY; Agnelli G
    Eur Heart J; 2014 Jul; 35(28):1844-55. PubMed ID: 24810388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay.
    Morishima Y; Kamisato C
    Am J Clin Pathol; 2015 Feb; 143(2):241-7. PubMed ID: 25596250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban.
    Brown KS; Wickremasingha P; Parasrampuria DA; Weiss D; Kochan J; Dishy V; He L; Shi M
    Thromb Res; 2015 Oct; 136(4):825-31. PubMed ID: 26298619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
    Giugliano RP; Ruff CT; Rost NS; Silverman S; Wiviott SD; Lowe C; Deenadayalu N; Murphy SA; Grip LT; Betcher JM; Duggal A; Dave J; Shi M; Mercuri M; Antman EM; Braunwald E;
    Stroke; 2014 Aug; 45(8):2372-8. PubMed ID: 24947287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.
    Samama MM; Mendell J; Guinet C; Le Flem L; Kunitada S
    Thromb Res; 2012 Apr; 129(4):e77-82. PubMed ID: 21851967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vitamin K deficiency from long-term warfarin anticoagulation does not alter skeletal status in male rhesus monkeys.
    Binkley N; Krueger D; Engelke J; Suttie J
    J Bone Miner Res; 2007 May; 22(5):695-700. PubMed ID: 17295605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vitamin K-dependent carboxylation of osteocalcin affects the efficacy of teriparatide (PTH(1-34)) for skeletal repair.
    Shimizu T; Takahata M; Kameda Y; Hamano H; Ito T; Kimura-Suda H; Todoh M; Tadano S; Iwasaki N
    Bone; 2014 Jul; 64():95-101. PubMed ID: 24731926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin.
    Fukuda T; Kamisato C; Honda Y; Matsushita T; Kojima T; Furugohri T; Morishima Y; Shibano T
    Thromb Res; 2013 Jun; 131(6):540-6. PubMed ID: 23673387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux.
    Wolzt M; Samama MM; Kapiotis S; Ogata K; Mendell J; Kunitada S
    Thromb Haemost; 2011 Jun; 105(6):1080-90. PubMed ID: 21544313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impairment of gamma carboxylation of circulating osteocalcin (bone gla protein) in elderly women.
    Plantalech L; Guillaumont M; Vergnaud P; Leclercq M; Delmas PD
    J Bone Miner Res; 1991 Nov; 6(11):1211-6. PubMed ID: 1666807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
    Honda Y; Kamisato C; Morishima Y
    Thromb Res; 2016 May; 141():17-21. PubMed ID: 26962981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of nonsynonymous mutations of factor X on the functions of factor X and anticoagulant activity of edoxaban.
    Noguchi K; Morishima Y; Takahashi S; Ishihara H; Shibano T; Murata M
    Blood Coagul Fibrinolysis; 2015 Mar; 26(2):117-22. PubMed ID: 24911450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.
    Zahir H; Brown KS; Vandell AG; Desai M; Maa JF; Dishy V; Lomeli B; Feussner A; Feng W; He L; Grosso MA; Lanz HJ; Antman EM
    Circulation; 2015 Jan; 131(1):82-90. PubMed ID: 25403645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide.
    Douxfils J; Chatelain B; Chatelain C; Dogné JM; Mullier F
    Thromb Haemost; 2016 Jan; 115(2):368-81. PubMed ID: 26510969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Edoxaban improves acute venous thromboembolism while preserving protein C and protein S levels.
    Yamazaki H; Yagi S; Torii Y; Amano R; Oomichi Y; Sangawa T; Fukuda D; Kadota M; Ise T; Ueno R; Hara T; Kusunose K; Matsuura T; Tobiume T; Yamaguchi K; Yamada H; Soeki T; Wakatsuki T; Akaike M; Sata M
    J Cardiol; 2018 Mar; 71(3):305-309. PubMed ID: 29100817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ex vivo reversal of the anticoagulant effects of edoxaban.
    Halim AB; Samama MM; Mendell J
    Thromb Res; 2014 Oct; 134(4):909-13. PubMed ID: 25179520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay.
    He L; Kochan J; Lin M; Vandell A; Brown K; Depasse F
    Thromb Res; 2017 Jul; 155():121-127. PubMed ID: 28535438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.
    Fuji T; Wang CJ; Fujita S; Kawai Y; Nakamura M; Kimura T; Ibusuki K; Ushida H; Abe K; Tachibana S
    Thromb Res; 2014 Dec; 134(6):1198-204. PubMed ID: 25294589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impaired carboxylation of osteocalcin in warfarin-treated patients.
    Menon RK; Gill DS; Thomas M; Kernoff PB; Dandona P
    J Clin Endocrinol Metab; 1987 Jan; 64(1):59-61. PubMed ID: 2878010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.
    Ogata K; Mendell-Harary J; Tachibana M; Masumoto H; Oguma T; Kojima M; Kunitada S
    J Clin Pharmacol; 2010 Jul; 50(7):743-53. PubMed ID: 20081065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.